Literature DB >> 19181295

Effects of the beta3-adrenergic agonist BRL 37344 on endothelial nitric oxide synthase phosphorylation and force of contraction in human failing myocardium.

Andreas Napp1, Klara Brixius, Christian Pott, Christoph Ziskoven, Birgit Boelck, Uwe Mehlhorn, Robert H G Schwinger, Wilhelm Bloch.   

Abstract

BACKGROUND: In nonfailing myocardium, beta(3)-adrenergic signaling causes a decrease in contractility via endothelial nitric oxide synthase (eNOS) activation and nitric oxide (NO) release. This study investigates the hypothesis that beta(3)-adrenergic signaling undergoes alterations in failing myocardium.
METHODS: We compared eNOS- and beta(3)-adrenoceptor expression using Western blot analysis in human nonfailing myocardium versus failing myocardium. With the use of immunohistochemistry, we investigated the distribution of the beta(3)-adrenoceptor protein and eNOS translocation and phosphorylation under basal conditions. beta(3)-adrenergic, eNOS activation, and inotropy were measured in failing myocardium using BRL37344 (BRL, a beta(3)-adrenoceptor agonist).
RESULTS: beta(3)-adrenoceptor expression was increased in failing myocardium. Under basal conditions, Akt- and eNOS(Ser1177) phosphorylation were reduced in failing myocardium. During stimulation with BRL in failing myocardium, a further dephosphorylation of eNOS(Ser1177) and Akt was observed, whereas eNOS(Ser114) phosphorylation was increased. These results suggest a deactivation of eNOS via beta(3)-adrenergic stimulation. Nevertheless, BRL decreased contractility in failing myocardium, but this effect was not observed in the presence of the NO blocker L-NMA. In failing myocardium, the beta(3)-adrenoceptor was predominantly expressed in endothelial cells. In the cardiomyocytes, the beta(3)-adrenoceptor was mainly located at the intercalated disks.
CONCLUSION: In failing cardiomyocytes, beta(3)-adrenergic stimulation seems to deactivate rather than activate eNOS. At the same time, beta(3)-adrenergic stimulation induced a NO-dependent negative inotropic effect. Because beta(3)-adrenoceptors are expressed mainly in the endothelium in failing myocardium, our observations suggest a paracrine-negative inotropic effect via NO liberation from the cardiac endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19181295     DOI: 10.1016/j.cardfail.2008.08.006

Source DB:  PubMed          Journal:  J Card Fail        ISSN: 1071-9164            Impact factor:   5.712


  20 in total

Review 1.  Beta-3 adrenoceptors as new therapeutic targets for cardiovascular pathologies.

Authors:  Chantal Gauthier; Bertrand Rozec; Boris Manoury; Jean-Luc Balligand
Journal:  Curr Heart Fail Rep       Date:  2011-09

2.  Human atrial β(1L)-adrenoceptor but not β₃-adrenoceptor activation increases force and Ca(2+) current at physiological temperature.

Authors:  Torsten Christ; Peter Molenaar; Paul M Klenowski; Ursula Ravens; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 3.  Cardiac β3 -adrenoceptors-A role in human pathophysiology?

Authors:  Ebru Arioglu-Inan; Gizem Kayki-Mutlu; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-22       Impact factor: 8.739

4.  Higher cardiorespiratory fitness attenuates the risk of atherosclerosis associated with ADRB3 Trp64Arg polymorphism.

Authors:  Motoyuki Iemitsu; Shumpei Fujie; Haruka Murakami; Kiyoshi Sanada; Hiroshi Kawano; Yuko Gando; Ryoko Kawakami; Noriko Tanaka; Motohiko Miyachi
Journal:  Eur J Appl Physiol       Date:  2014-03-23       Impact factor: 3.078

Review 5.  Agonist-induced desensitisation of β3 -adrenoceptors: Where, when, and how?

Authors:  Katerina Okeke; Stephane Angers; Michel Bouvier; Martin C Michel
Journal:  Br J Pharmacol       Date:  2019-04-07       Impact factor: 8.739

6.  Cardioprotective effect of beta-3 adrenergic receptor agonism: role of neuronal nitric oxide synthase.

Authors:  Xiaolin Niu; Vabren L Watts; Oscar H Cingolani; Vidhya Sivakumaran; Jordan S Leyton-Mange; Carla L Ellis; Karen L Miller; Konrad Vandegaer; Djahida Bedja; Kathleen L Gabrielson; Nazareno Paolocci; David A Kass; Lili A Barouch
Journal:  J Am Coll Cardiol       Date:  2012-05-29       Impact factor: 24.094

Review 7.  Are there functional β₃-adrenoceptors in the human heart?

Authors:  Martin C Michel; Sian E Harding; Richard A Bond
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

8.  Response by Simpson et al to Letter Regarding Article, "Adrenergic Receptors in Individual Ventricular Myocytes: the Beta-1 and Alpha-1B Are in All Cells, the Alpha-1A Is in a Subpopulation, and the Beta-2 and Beta-3 Are Mostly Absent".

Authors:  Paul C Simpson; Bat-Erdene Myagmar; Philip M Swigart; Simon Melov; Anthony J Baker
Journal:  Circ Res       Date:  2017-06-09       Impact factor: 17.367

9.  Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy.

Authors:  Danielle M Trappanese; Yuchuan Liu; Ryan C McCormick; Alessandro Cannavo; Gayani Nanayakkara; Marina M Baskharoun; Harish Jarrett; Felix J Woitek; D Michael Tillson; A Ray Dillon; Fabio A Recchia; Jean-Luc Balligand; Steven R Houser; Walter J Koch; Louis J Dell'Italia; Emily J Tsai
Journal:  Basic Res Cardiol       Date:  2014-12-06       Impact factor: 17.165

Review 10.  A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling.

Authors:  Jihong Yang; Yufeng Liu; Xiaohui Fan; Zheng Li; Yiyu Cheng
Journal:  Heart Fail Rev       Date:  2014-11       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.